M.D., Polymeropoulos addresses the rejection Vanda received in September 2024, deeming the agency’s review process as “faulty,” according to the Jan. 8 letter (PDF). The biotech had ...

Oncolytics Biotech Inc. ONCY has been struggling lately, but the selling pressure may be coming to an end soon. That is because ONCY recently saw a Hammer Chart Pattern which can signal that the ...

April 23 (Reuters) - Moleculin Biotech Inc: * MOLECULIN BIOTECH INC - ON APRIL 23, CO RECEIVED LETTER FROM NASDAQ NOTIFYING COMPANY THAT IT HAD REGAINED COMPLIANCE WITH NASDAQ LISTING RULE ...